



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: MEE-005 APPLICANT(S): Adamis et al. SERIAL NO.: 09/478,099 FILING DATE: January 5, 2000 GROUP: 1632					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
Am2	A98	5,770,580	6/23/98	Ledley et al.	514	44			
Am2	A99	5,792,751	8/11/98	Ledley et al.	514	44			
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
Am2	B13	97/15330	5/1/97	WO					
Am2	B14	97/37542	10/16/97	WO					
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
Am2	C9	Advances in CMV Management: Fomivirsen (Vitravene®) Approved" <u>PI Perspective</u> (1998) 26: 7.							
	C10	Henry et al. "Antiviral Activity and Ocular Kinetics of Antisense Oligonucleotides Designed to Inhibit CMV Replication" <u>Invest. Ophthalmol. Vis. Sci.</u> (2001) 42(11): 2646-2651. Duplicate							
Am2	C11	Leeds et al. "Pharmacokinetics of a Potential Human Cytomegalovirus Therapeutic, a Phosphorothioate Oligonucleotide, After Intravitreal Injection in the Rabbit" <u>Drug Metab. and Disposition</u> (1997) 25(8): 921-926.							
Am2	C12	de Smet et al. "Fomivirsen - a Phosphorothioate Oligonucleotide for the Treatment of CMV Retinitis" <u>Ocular Immunology and Inflammation</u> (1999) 7(3-4): 189-198.							
Am2	C13	"Fomivirsen Approved for CMV Retinitis: First Antisense Drug" <u>AIDS Treat News</u> (1998) 302: 7							
Am2	C14	"New CMV Drug Won't Replace Other Therapies" <u>AIDS Alert</u> (1998) 124-126.							
Am2	C15	Roehr "Fomivirsen Approved for CMV Retinitis" <u>J. Int'l. Assoc. of Physicians in AIDS Care</u> (1998) 14-16.							
Am2	C16	Robinson et al. "Oligonucleotides Inhibit Retinal Neovascularization in a Murine Model of Proliferative Retinopathy" <u>Proc. Natl. Acad. Sci. USA</u> (1996) 4851-4856.							
EXAMINER		Anne-Marie Zalk				DATE CONSIDERED 1/27/04			



SHEET 2 OF 2

FORM PTO - 1449		ATTORNEY DOCKET NO.: MEE-005	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Adamis et al.	
		SERIAL NO.: 09/478,099	
		FILING DATE: January 5, 2000 GROUP: 1632	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
Amz	C17	Bhisitkul <i>et al.</i> "Antisense Oligonucleotides Against Vascular Endothelial Growth Factor in a Non-Human Primate Model of Ocular Angiogenesis" <u>Invest. Ophthalmol. Vis. Sci.</u> (1998) 39(4) Abstract.	
Amz	C18	Carrasquillo <i>et al.</i> "Controlled Delivery of the Anti-VEGF Aptamer EYE001 with Poly(lactic-co-glycolic) Acid Microspheres" <u>Invest. Ophthalmol. Vis. Sci.</u> (2003) 44(1): 290-299.	
Amz	C19	Henry <i>et al.</i> "Antiviral Activity and Ocular Kinetics of Antisense Oligonucleotides Designed to Inhibit CMV Replication" <u>Invest. Ophthalmol. Vis. Sci.</u> (2001) 42(11): 2646-2651.	
Amz	C20	Masuda <i>et al.</i> "Gene Transfer with Liposomes to the Intraocular Tissues by Different Routes of Administration" <u>Invest. Ophthalmol. Vis. Sci.</u> (1996) 37(9): 1914-1920.	
Amz	C21	L2 Tian <i>et al.</i> "Phenotype Correction in Retinal Pigment Epithelium in Murine Mucopolysaccharidosis VII by Adenovirus-mediated Gene Transfer" <u>Proc. Natl. Acad. Sci. USA</u> (1995) 92: 7700-7704.	
Amz	C22	Mashhour <i>et al.</i> "In vivo Adenovirus-mediated Gene Transfer into Ocular Tissues" <u>Gene Therapy</u> (1994) 1: 122-126.	
Amz	C23	Tanelian <i>et al.</i> "Controlled Gene Gun Delivery and Expression of DNA Within the Cornea" <u>BioTechniques</u> (1997) 23(3): 484-488.	
EXAMINER <i>Anne-Marie Zalk</i>		DATE CONSIDERED <i>1/27/04</i>	